Mefitel film for radiation dermatitis: it works, why not?

Published Date: 13 Mar 2023

According to the results of a phase 3 trial, the use of silicone film before radiotherapy can reduce the incidence of radiodermatitis, so why not use it?

Read Full News

Latest News

Make the Diagnosis: This Cyst Is Asymptomatic. Is It a Problem?

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Targeted Oral Drug Plus UV Therapy May Help in Extensive Vitiligo

Positive signs in phase II test

Novel Drug Eases Disease Activity in Dermatomyositis

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Biomarker May Flag Humira Responders in Hidradenitis Suppurativa

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

What Botox Teaches Us About Serendipity in Clinical Encounters

Don't forget the power of a strong doctor-patient relationship

Make the Diagnosis: Are Her Nail Symptoms Part of a Larger Picture?

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Latest News

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Positive signs in phase II test

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

Don't forget the power of a strong doctor-patient relationship

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

News All Time

Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage Trial

Impressive responses with barzolvolimab in cold urticaria, symptomatic dermographism

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

Significant reduction in hives and itch in antihistamine-resistant patients

50 Years After City Halted Prison Medical Testing, Families Seek Reparations

"No amount of money can replace what was done to me," said one former prisoner

Make the Diagnosis: She Feels Fine, But Why Do Her Fingers Look Like This?

A 38-year-old woman visited her doctor about itchy, raised spots that developed on her fingers 5 days prior. Can you diagnose the patient?

A Look at Kamala Harris' Medical History

Veep in "excellent health," doctor says, with history that includes seasonal allergies, urticaria

Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma

Two-year survival in second line for patients with BRAF/NRAS wild-type tumors

Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene

Study findings suggest cold storage may prevent breakdown into carcinogen

Make the Diagnosis: It’s Ugly, and It Hurts. What the Heck Is It?

A 29-year-old woman visited the doctor for a painful rash that developed on her arm 1 day after working on a landscaping project that involved pulling weeds under intense sunlight. Can you diagnose the patient?

Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds

But only a minority achieved minimal disease activity within 16 weeks

Lebrikizumab Wins FDA Approval for Eczema

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

Stopping JAK Inhibitor for Severe Alopecia Areata Led to Hair Loss

Long-term maintenance therapy is necessary, researchers caution

IL-31 Drug for Itchy Nodular Skin Disease Gets Thumbs Up From FDA

Nemolizumab significantly improved itch, nodules, and sleep disturbance at 16 weeks

IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

Psoriasis Control Maintained Long Term With Extended Dosing Interval of Guselkumab

More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing

Common Antibiotics Linked With Serious Skin Reactions in Older Adults

Sulfonamides and cephalosporins the worst offenders, study finds

Recommended News For You

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds

According to new studies, some cancer patients can safely forego radiation therapy.

Scientists are investigating the prevention of recurrent breast cancer, which frequently results in death.

Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

Recommended Articles For You

The Basics of M.C.V Normal Range for Better Health Management 

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options 

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology 

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

5.

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

1.

The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment

2.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

3.

Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy

4.

Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer

5.

Transfusing the Future: Exploring the Possibilities of Blood Transfusions

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

4.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot